Piper Sandler raised the firm’s price target on Verona Pharma (VRNA) to $160 from $76 and keeps an Overweight rating on the shares. Verona Pharma remains one of Piper’s top 2025 picks, where Street ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price ...

Ligand Pharmaceuticals offers investors exposure to dozens of therapies, reducing risk and increasing upside potential. See ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price target to $116 from $92 while reiterating a Buy rating.

Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care Stephen Ayers Sat, Sep. 14, 2024 11 Comments. Verona Pharma: A Post FDA Approval Analysis Bret Jensen Tue, Sep. 10, 2024 8 ...

Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures.

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.

Verona Weather Forecasts. Weather Underground provides local & long-range weather forecasts, weatherreports, maps & tropical weather conditions for the Verona area.